
The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss ongoing research to watch in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, highlight ongoing research efforts that may further transform the management of EGFR-mutated non–small cell lung cancer. Rosner discusses emerging therapeutic strategies, including next-generation targeted therapies and novel combination approaches designed to overcome resistance. Alder emphasizes the potential for biomarker-driven treatment selection and ongoing clinical trials to refine sequencing strategies and improve long-term patient outcomes.






